In an era when health-related information is often overwhelming and contradictory, HT Lifestyle has launched a reader-centric initiative. Every week, we invite HT readers to share their most pressing medical concerns regarding a specific health issue. We then take those ‘burning questions’ straight to the country’s leading medical experts to provide you with clarity, comfort and clinically backed solutions. Read also | HT Health Talk: You asked, our experts answered how to manage summer migraines
This week, the spotlight is on GLP-1 receptor agonists such as Ozempic, Mounjaro, and Wegovi. Although these drugs are being touted as ‘miracle’ shots for weight loss, they come with a complex set of side effects and long-term considerations, especially for the Indian population. Read this also Amid growing trend of pre-wedding weight loss injections in India, doctors have warned ‘Maunjaro brides’ against taking risky shortcuts.
To break down the science, we turned to Dr Narendra BS, chief consultant, endocrinology and diabetology at Aster Whitefield Hospital, Bengaluru. With 11 years of experience, Dr. Narendra explains the most commonly asked questions:
1. What are the most serious long-term risks of GLP-1 drugs that Indians should know about?
Use of GLP-1 receptor agonists including Ozempic, Vegovy and monjaroProvides effective treatment but has potential risks if used for extended periods. Frequently reported concerns include persistent gastrointestinal symptoms such as nausea leading to vomiting and delayed gastric emptying that impacts nutrition. Body weight begins to decrease, which increases the risk of developing gallstones and gall bladder disease. Studies show that people who already have risk factors have a small but significant risk of pancreatitis. Researchers are still studying the risks of developing thyroid C-cell tumors, which is unclear because human data are insufficient. The Indian population experienced muscle loss and fatigue and micronutrient deficiencies due to prolonged periods of hunger, resulting in dietary protein intake below recommended levels. 2025 Physicians participating in medical discussions should assess kidney function and hydration, as low oral intake may increase the risk of dehydration-related medical problems in some patients.
2. What are the minimum and maximum ages for Ozempic, Vegovy etc.?
GLP-1 medications have specific age ranges for each medication and its specified medical purpose. Vegovi is approved in several countries for adolescents aged 12 years and older who meet criteria for obesity, while Ozempic is primarily indicated for adults. type 2 diabetes. Medical practitioners need to handle patients over the age of 65 as they face increased risks from weakness and muscle deterioration and their existing health problems. Seniors are at greater risk of unintentional weight loss when it results in a substantial loss of lean muscle mass. In the medical profession these drugs are used on young patients when they experience metabolic disorders as well as extreme obesity after their attempts to lose weight through lifestyle changes have failed. Determining eligibility requires assessment of metabolic health and risk factors and overall ability to tolerate the drug in a controlled medical setting, rather than using age as the sole eligibility criterion.
3. Is Ozempic addictive? Can you depend on it?
GLP-1 drugs like Ozempic are not addictive in the traditional sense because they do not activate the brain’s reward pathways, which causes drug addiction. However, many patients develop what can be called physical dependence. The drugs reduce appetite by delaying stomach emptying while increasing the feeling of fullness, helping users stick to their calorie-restriction goals. Discontinuing the medication reverses these effects, causing people to experience increased appetite and subsequent weight loss. People who lack a proper lifestyle may develop a perception of “dependence” on the substance. Long-term studies discussed in the recent clinical literature show that most patients regain lost weight after stopping treatment. Medications should be considered as elements of chronic disease management, which require permanent dietary changes, behavioral modifications, and physical activity adjustments to achieve long-term results.
4. Does a low-protein Indian diet increase muscle/bone loss while on Ozempic?
Risk of muscle loss during GLP-1 drug treatment increases when Indian population follows their usual dosage lean protein Diet pattern. The medications suppress appetite, thereby reducing calorie intake, including protein. The body needs protein to prevent the breakdown of lean muscle, which it uses for energy during weight loss. Loss of muscle mass reduces both strength and functional capacity and reduces basal metabolic rate, complicating long-term weight maintenance. The relationship between muscle health and bone health creates an indirect pathway that, over time, reduces bone density. Clinical observations from 2025 indicate that people need to consume adequate protein from pulses, dairy products, eggs, or low-fat meat along with resistance training. The absence of these measures results in individuals losing more muscle than fat, which creates negative effects on their metabolic functioning and skeletal health.
5. Does Ozempic actually cause bone loss, or does it just cause weight loss?
Current evidence suggests that patients taking GLP-1 drugs experience bone loss because their body weight decreases rapidly, not because of the drugs they take. Losing body weight reduces mechanical stress on the bones, which reduces bone excitability and subsequently reduces bone density. Decreased appetite reduces consumption of calcium, vitamin D and protein, which are important for bone health. The 2025 analysis shows that the rate of weight loss is the primary factor determining how bones will change in response to the drug. The risk should not be considered insignificant. Bone strength will decrease over time unless individuals receive adequate nutrition and do not engage in both weight lifting and resistant physical activities. People who already have risk factors osteoporosis Their bone health should be monitored closely.
6. Could GLP-1 drugs increase the risk of osteoporosis or fractures in Indians over 40?
People who are under 40 need to handle the weight loss process carefully, otherwise they will be more likely to experience fractures. Low bone mineral density in Indians is caused by inadequate calcium intake and general vitamin D deficiency. The use of GLP-1 drugs results in significant weight loss, which automatically reduces bone density if users lack proper nutrition and physical training. Existing research evidence does not establish that these medications increase fracture risk as an independent factor. The risk appears to be multifactorial – linked to age, baseline bone health and lifestyle factors. Implementing preventive measures requires adequate protein intake and consistent strength training, as well as proper calcium and vitamin D levels. Periodic bone density tests are necessary for high-risk individuals as they enable doctors to identify and treat osteoporosis at an early stage.
7. Does strength training prevent Ozempic-related bone loss?
The most effective way to combat muscle and bone loss during weight loss with GLP-1 drugs is strength training. The process of resistance exercise creates mechanical stress, which stimulates muscle protein synthesis and bone growth. This method enables people to maintain their body weight while maintaining their bone density, even if they eat fewer calories. Medical guidelines recommend that doctors use GLP-1 treatment with exercise programs that include resistance training, three times a week or more. This method improves both physical strength and functional ability, increases the body’s metabolism, and aids in the maintenance of weight loss over time. People who want to lose weight need to do strength training because it helps them lose fat instead of muscle, which is an unwanted result. process required resistance exercise Because it helps people achieve better results while reducing the health risks of losing weight quickly.
8. Do you have to take Ozempic forever to keep the weight off?
Doctors prescribe GLP-1 medications as permanent treatments because the medications treat permanent medical conditions including obesity and metabolic disorders. Recent research findings show that when people stop taking Ozempic, their body weight increases as their appetite returns to normal and their natural metabolic processes resume. However, lifelong use is not mandatory for everyone. People who lose weight permanently can maintain their new weight after establishing permanent changes in their eating habits, exercise routines, and everyday activities. People face difficulties when they need to maintain permanent changes in lifestyle without taking medications. Doctors develop unique treatment plans based on their patients’ goals, their treatment outcomes, and their medical history. Lasting results require patients to maintain fundamental changes in their lifestyle, while they may need to use treatment methods for several months or longer.
9. Is it harder to lose weight the second time you go on Ozempic?
The amount of weight loss during second GLP-1 treatment depends on the patient’s metabolic processes, lifestyle choices, and treatment compliance. After weight loss the human body enters a state of energy conservation as metabolic processes become more efficient, slowing down the pace of weight loss. The efficacy of the drug does not diminish with time. Patients who repeat treatment with improved diet and exercise strategies have adequate results. The main factor influencing outcomes is human behavior; People who work on previous deficiencies in their food intake or physical activity achieve better results. Clinical evidence shows that varying rates of weight loss exist among patients, yet they can all achieve substantial health improvements. Patients need to develop realistic expectations about their weight loss process because treatment requires a comprehensive program that runs throughout their weight-control efforts.
10. Can Ozempic cause pancreatitis, and is the risk higher for Indians with gallstones?
pancreatitis The risk associated with GLP-1 drugs like Ozempic exists as a minor medical risk that is recognized by doctors. The risk of liver disease increases in people who experience gallstone disease and elevated triglyceride levels and who have already shown symptoms of pancreatitis. Due to medicines, patients start losing weight rapidly, which increases the risk of gallstones, which can cause inflammation in the pancreas. Indian population faces this risk as gallstones occur frequently in their community. Doctors need to thoroughly evaluate patients before starting treatment, as well as monitor their symptoms, which include severe abdominal pain that spreads to the back, nausea, and vomiting. Early diagnosis of pancreatitis is required in the medical field as untreated cases can turn into serious complications. Health care systems need to focus on patient education and proper risk assessment procedures as they help reduce patient complications, even if the actual risk remains minimal.
Note to readers: This article is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your doctor with any questions you may have about a medical condition.
